Euclidean Capital LLC

CIK: 0001825034Latest portfolio: $369.4M · Q4 2025

Holdings

12

Total Value

$369.4M

New Positions

1

Closed Positions

0

Top Holdings

#StockSharesValue% PortfolioChangeType
1
VEUVANGUARD INTL EQUITY INDEX F
2,990,084$219.9M59.53%+412K
2
VTVVANGUARD INDEX FDS
520,000$99.3M26.88%NEW
3
INDAISHARES TR
369,600$20.0M5.41%
4
FHTXFOGHORN THERAPEUTICS INC
1,573,761$8.5M2.30%
5
ORICORIC PHARMACEUTICALS INC
989,410$8.1M2.19%
6
PMVPPMV PHARMACEUTICALS INC
2,627,643$3.3M0.89%
7
SPYSPDR S&P 500 ETF TR
4,104$2.8M0.76%
8
RAPTRAPT THERAPEUTICS INC
82,234$2.8M0.75%
9
ALECALECTOR INC
1,307,858$2.0M0.55%
10
SRZNSURROZEN INC
87,696$2.0M0.54%
11
TNYATENAYA THERAPEUTICS INC
1,015,705$722K0.20%
12
SRZNWSURROZEN INC
170,833$3K0.00%

Quarterly Changes

New Positions

Closed Positions

No closed positions this quarter

Increased Positions

NameSharesChange
VEU3.0M+412K

Decreased Positions

No decreased positions

Sector Breakdown

Healthcare0.0% ($8498809332842784768.0T)
Financial Services0.0% ($21995099314.2T)

Filing History

QuarterFiling DatePortfolio ValueHoldings
Q4 2025Feb 17, 2026$369.4M12
Q3 2025Nov 14, 2025$238.0B11
Q2 2025Aug 14, 2025$305.7B11
Q1 2025May 15, 2025$266.1B11
Q4 2024Feb 14, 2025$736.7B11

Fund Information

CIK0001825034
Most Recent FilingFeb 17, 2026
Number of Filings5

Euclidean Capital LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $369.4M across 12 holdings. The largest position is VANGUARD INTL EQUITY INDEX F (VEU), representing 59.5% of the portfolio. Compared to the previous quarter, the fund opened 1 new positions and closed 0 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.